ArticleFrontiers in immunology2026
Evaluating glycolysis-associated biomarkers for radiotherapy sensitivity in head and neck squamous cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck squamous cell carcinoma (HNSC) present a significant treatment challenge due to variability in radiotherapy response, where glycolysis may play a pivotal role in modulating sensitivity. This study aimed to develop a glycolysis-associated biomarker for radiotherapy sensitivity. Methods: We analyzed gene expression and clinical data from 491 HNSC patients and single-cell RNA sequencing to assess glycolysis activity in HNSC. A glycolysis-associated radiosensitivity index (RI) was developed using Cox regression analysis of glycolysis-related genes. Immune microenvironment profiles, functional pathways, and therapeutic responses were analyzed via using ssGSEA, CIBERSORT, TIDE, and pRRophetic. Results: The study identified that low glycolytic activity significantly correlates with improved overall survival in HNSC patients following radiotherapy, while high glycolytic activity is associated with radio-resistance. Using a RI based on glycolysis-related gene expression, we successfully stratified patients into RS and RR groups. RS tumors exhibited significantly higher immune cell infiltration and lower TIDE scores, indicating a better response to immunotherapy. In contrast, RR tumors showed increased sensitivity to chemotherapy agents, including platinum and EGFR/HER2 inhibitors. Single-cell RNA sequencing revealed that high-glycolysis tumors had diminished immune cell infiltration, particularly lacking CD8+ T cells, supporting the notion of immune evasion. Conclusion: This study emphasizes the importance of glycolytic activity in influencing radiotherapy sensitivity and highlights the potential of the RI as a predictive biomarker, paving the way for improved personalized treatment strategies in HNSC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.